Ozempic (semaglutide) shortage collection
Increased global demand for semaglutide products is impacting availability of Ozempic (semaglutide) in Australia. Alerts on the shortage of Trulicity (dulaglutide) and Mounjaro (tirzepatide) are also accessible from this collection.
Filter results
You can narrow down the results using the filters.
Type
Topics
- Shortages (10)
- Prescription medicines (4)
- Advertising (3)
- Alert/Advisory (3)
- Medicines safety (3)
- Regulatory compliance (3)
- Weight loss products (3)
- Import and export (2)
- Therapeutic goods regulation (2)
- Australian Register of Therapeutic Goods (ARTG) (1)
- Legislation (1)
- Manufacturing (1)
- Safety (1)
Read current information and updates at:
About the Ozempic (semaglutide) shortage 2022 and 2024
About the Trulicity (dulaglutide) shortage 2022 and 2023
The pharmaceutical company that supplies Ozempic, Novo Nordisk, has recently advised the TGA and the Ozempic Medicine Shortage Action Group that supply throughout the rest of the year and into 2024 will be limited. Currently we are asking health professionals not to prescribe Ozempic to new patients to conserve supply for patients who are already stabilised on this medicine and who do not have suitable alternatives.
Visit the Medicine shortage reports database to search for all medicines in shortage and find information about management actions.
Collection content
-
Medicine shortage alertsPharmaceutical company Novo Nordisk has advised us that a new brand of semaglutide approved for chronic weight management, Wegovy, will be available in Australia from early August 2024.
-
BlogSome online health clinics are advertising and selling compounded medicines. However, it is important to know that compounded products are not identical to TGA approved products.
-
Safety alertsWe are aware of an emerging trend for telehealth providers to offer compounded semaglutide-like products. Compounded semaglutide-like products are ‘unapproved’ therapeutic goods and have not been evaluated by us for safety, quality and efficacy.
-
Medicine shortage alertsThe availability of all strengths of Mounjaro (tirzepatide) will be limited until 31 August 2024, due to unexpected high demand. Patients and healthcare professionals should check the Medicine Shortage Reports Database for the latest supply information.
-
Medicine shortage alertsRead advice about not prescribing Ozempic to new patients unless there are no suitable alternatives or there is a compelling clinical reason.
-
Medicine shortage alertsThe supply of Ozempic (semaglutide) in Australia is improving however the shortage continues. Stay updated about how the shortage impacts you.
-
Safety alertsThe TGA has detected fake semaglutide, also known as Ozempic, being illegally imported into Australia.
-
Media releasesThe TGA is aware of several scams targeting consumers seeking semaglutide (Ozempic). Consumers are strongly advised not to use products unless they have come from a trusted source.
-
NewsSupplies of Ozempic (semaglutide) have begun distribution in Australia but will remain quite limited for some time.
-
NewsA warning to social media influencers and advertisers not to advertise this prescription medicine.
This webpage on the TGA website was printed on 12 Sep 2024. Printed content may be out of date. For up-to-date information, always refer to the digital version: https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/about-ozempic-semaglutide-shortage-2022-2024/ozempic-semaglutide-shortage-collection